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It is essential that the medical profession play a central role
in critically evaluating the evidence related to drugs, de-
vices, and procedures for the detection, management, orgery c December 2011
Gersh et al Clinical Guidelineprevention of disease. Properly applied, rigorous, expert
analysis of the available data documenting absolute and rel-
ative benefits and risks of these therapies and procedures
can improve the effectiveness of care, optimize patient out-
comes, and favorably affect the cost of care by focusing re-
sources on the most effective strategies. One important use
of such data is the production of clinical practice guidelines
that, in turn, can provide a foundation for a variety of other
applications such as performance measures, appropriate-
ness use criteria, clinical decision support tools, and quality
improvement tools.
The American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
jointly engaged in the production of guidelines in the area
of cardiovascular disease since 1980. The ACCF/AHA
Task Force on Practice Guidelines (Task Force) is charged
with developing, updating, and revising practice guidelines
for cardiovascular diseases and procedures, and the Task
Force directs and oversees this effort. Writing committees
are charged with assessing the evidence as an independent
group of authors to develop, update, or revise recommenda-
tions for clinical practice.
Experts in the subject under consideration have been se-
lected from both organizations to examine subject-specific
data and write guidelines in partnership with representatives
from other medical practitioner and specialty groups. Writ-
ing committees are specifically charged to perform a formal
literature review, weigh the strength of evidence for or
against particular tests, treatments, or procedures, and in-
clude estimates of expected health outcomes where data ex-
ist. Patient-specific modifiers, comorbidities, and issues of
patient preference that may influence the choice of tests
or therapies are considered. When available, information
from studies on cost is considered, but data on efficacy
and clinical outcomes constitute the primary basis for rec-
ommendations in these guidelines.
In analyzing the data and developing the recommenda-
tions and supporting text, the writing committee used
evidence-based methodologies developed by the Task
Force, which are described elsewhere.1 The committee re-
viewed and ranked evidence supporting current recom-
mendations with the weight of evidence ranked as Level
A if the data were derived from multiple randomized clin-
ical trials (RCTs) or meta-analyses. The committee
ranked available evidence as Level B when data were de-
rived from a single RCT or nonrandomized studies. Evi-
dence was ranked as Level C when the primary source
of the recommendation was consensus opinion, case stud-
ies, or standard of care. In the narrative portions of these
guidelines, evidence is generally presented in chronolog-
ical order of development. Studies are identified as obser-
vational, retrospective, prospective, or randomized when
appropriate. For certain conditions for which inadequate
data are available, recommendations are based on expertThe Journal of Thoracic and Carconsensus and clinical experience and ranked as Level
C. An example is the use of penicillin for pneumococcal
pneumonia, for which there are no RCTs and treatment is
based on clinical experience. When recommendations at
Level C are supported by historical clinical data, appro-
priate references (including clinical reviews) are cited if
available. For issues where sparse data are available, a sur-
vey of current practice among the clinicians on the
writing committee was the basis for Level C recommen-
dations and no references are cited. The schema for Clas-
sification of Recommendations and Level of Evidence is
summarized in Table 1, which also illustrates how the
grading system provides an estimate of the size and
the certainty of the treatment effect. A new addition to
the ACCF/AHA methodology is separation of the Class
III recommendations to delineate whether the recommen-
dation is determined to be of ‘‘no benefit’’ or associated
with ‘‘harm’’ to the patient. In addition, in view of the in-
creasing number of comparative effectiveness studies,
comparator verbs and suggested phrases for writing rec-
ommendations for the comparative effectiveness of one
treatment/strategy with respect to another for Class of
Recommendation I and IIa, Level of Evidence A or B
only have been added.
The Task Force makes every effort to avoid actual, poten-
tial, or perceived conflicts of interest that may arise as a re-
sult of relationships with industry and other entities (RWI)
among the writing committee. Specifically, all members of
the writing committee, as well as peer reviewers of the
document, are required to disclose all relevant relation-
ships and those 12 months prior to initiation of the writing
effort. The policies and procedures for RWI for this guide-
line were those in effect at the initial meeting of this com-
mittee (March 28, 2009), which included 50% of the
writing committee with no relevant RWI. All guideline rec-
ommendations require a confidential vote by the writing
committee and must be approved by a consensus of the
members voting. Members who were recused from voting
are indicated on the title page of this document with de-
tailed information included in Appendix 1. Members
must recuse themselves from voting on any recommenda-
tions where their RWI apply. If a writing committee mem-
ber develops a new RWI during his/her tenure, he/she is
required to notify guideline staff in writing. These state-
ments are reviewed by the Task Force and all members
during each conference call and/or meeting of the writing
committee and are updated as changes occur. For detailed
information regarding guideline policies and procedures,
please refer to the ACCF/AHA methodology and policies
manual.1 RWI pertinent to this guideline for authors and
peer reviewers are disclosed in Appendixes 1 and 2, re-
spectively. Comprehensive disclosure information for the
Task Force is also available online at http://www.
cardiosource.org/ACC/About-ACC/Leadership/Guidelines-diovascular Surgery c Volume 142, Number 6 1305
TABLE 1. Applying classification of recommendation and level of evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *Data
available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction,
history of heart failure, and prior aspirin use. yFor comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of
comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
Clinical Guideline Gersh et aland-Documents-Task-Forces.aspx. The work of the writing
committee was supported exclusively by the ACCF and
AHA without commercial support. Writing committee
members volunteered their time for this effort.
The ACCF/AHA practice guidelines address patient
populations (and healthcare providers) residing in North
America. As such, drugs that are currently unavailable in
North America are discussed in the text without a specific
class of recommendation. For studies performed in large
numbers of subjects outside of North America, each writ-
ing group reviews the potential impact of different practice
patterns and patient populations on the treatment effect and1306 The Journal of Thoracic and Cardiovascular Suron the relevance to the ACCF/AHA target population to
determine whether the findings should inform a specific
recommendation.
The ACCF/AHA practice guidelines are intended to assist
healthcare providers in clinical decision making by describ-
ing a range of generally acceptable approaches for the diag-
nosis, management, and prevention of specific diseases or
conditions. These practice guidelines represent a consensus
of expert opinion after a thorough review of the available cur-
rent scientific evidence and are intended to improve patient
care. The guidelines attempt to define practices that meet
the needs of most patients in most circumstances. Thegery c December 2011
Gersh et al Clinical Guidelineultimate judgment regarding care of a particular patient must
be made by the healthcare provider and patient in light of all
the circumstances presented by that patient. Thus, there are
situations in which deviations from these guidelines may
be appropriate. Clinical decision making should consider
the quality and availability of expertise in the area where
care is provided.When these guidelines are used as the basis
for regulatory or payer decisions, thegoal should be improve-
ment in quality of care. The Task Force recognizes that situ-
ations arise for which additional data are needed to better
inform patient care; these areas will be identified within
each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if they are followed.
Because lack of patient understanding and adherence may
adversely affect outcomes, physicians and other healthcare
providers should make every effort to engage the patient’s
active participation in prescribed medical regimens and
lifestyles.
The guidelinewill be reviewed annually by the Task Force
and considered current unless it is updated, revised, or with-
drawn from distribution. The full-text version1a of the guide-
line is e-published in the Journal of the American College of
Cardiology andCirculation and is posted on the ACC (www.
cardiosource.org) and AHA (my.americanheart.org) World
Wide Web sites. Guidelines are official policy of both the
ACCF and AHA.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this document are, when-
ever possible, evidence based. An extensive evidence re-
view was conducted through January 2011. Searches were
limited to studies, reviews, and other evidence conducted
in human subjects and published in English. Key search
words included, but were not limited to, hypertrophic car-
diomyopathy (HCM), surgical myectomy, ablation, exer-
cise, sudden cardiac death (SCD), athletes, dual-chamber
pacing, left ventricular outflow tract (LVOT) obstruction,
alcohol septal ablation, automobile driving and implant-
able cardioverterdefibrillators (ICDs), catheter ablation,
defibrillators, genetics, genotype, medical management,
magnetic resonance imaging, pacing, permanent pacing,
phenotype, pregnancy, risk stratification, sudden death in
athletes, surgical septal myectomy, and septal reduction.
References selected and published in this document are rep-
resentative and not all-inclusive.
1.2. Organization of the Writing Committee
The committee was composed of physicians and cardiac
surgeons with expertise in HCM, invasive cardiology,The Journal of Thoracic and Carnoninvasive testing and imaging, pediatric cardiology, elec-
trophysiology, and genetics. The committee included repre-
sentatives from the American Association for Thoracic
Surgery, American Society of Echocardiography, American
Society of Nuclear Cardiology, Heart Failure Society of
America, Heart Rhythm Society, Society for Cardiovascu-
lar Angiography and Interventions, and the Society of
Thoracic Surgeons.
1.3. Document Review and Approval
This document was reviewed by 2 outside reviewers
nominated by both the ACCF and AHA, as well as 2 re-
viewers each from the American Association for Thoracic
Surgery, American Society of Echocardiography, American
Society of Nuclear Cardiology, Heart Failure Society of
America, Heart Rhythm Society, Society for Cardiovascu-
lar Angiography and Interventions, and the Society of Tho-
racic Surgeons. Other content reviewers included members
from the ACCFAdult Congenital and Pediatric Cardiology
Council, ACCF Surgeons’ Scientific Council, and ACCF
Interventional Scientific Council. All information on re-
viewers’ RWI was distributed to the writing committee
and is published in this document (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACCF and the AHA and endorsed by
the American Association for Thoracic Surgery, American
Society of Echocardiography, American Society of Nuclear
Cardiology, Heart Failure Society of America, Heart
Rhythm Society, Society for Cardiovascular Angiography
and Interventions, and Society of Thoracic Surgeons.
1.4. Scope of the Guideline
Although there are reports of this disease dating back to
the 1800s, the first modern pathologic description was pro-
vided over 50 years ago by Teare2 and the most important
early clinical report by Braunwald et al in 1964.3
The impetus for the guidelines is based on an apprecia-
tion of the frequency of this clinical entity and a realization
that many aspects of clinical management, including the use
of diagnostic modalities and genetic testing, lack consen-
sus. Moreover, the emergence of 2 different approaches to
septal reduction therapy (septal myectomy and alcohol sep-
tal ablation) in addition to the ICD has created considerable
controversy. The discussion and recommendations about
the various diagnostic modalities apply to patients with es-
tablished HCM and to a variable extent to patients with
a high index of suspicion of the disease.
Although the Task Force was aware of the lack of high
levels of evidence regarding HCM provided by clinical tri-
als, it was believed that a guideline document based on ex-
pert consensus that outlines the most important diagnostic
and management strategies would be helpful.
To facilitate ease of use, it was decided that recommenda-
tions in the pediatric and adolescent age groups would notdiovascular Surgery c Volume 142, Number 6 1307
Clinical Guideline Gersh et alappear as a separate section but instead would be integrated
into the overall content of the guideline where relevant.
2. RECOMMENDATIONS FOR HCM
2.1. Genetic Testing Strategies/Family Screening—
Recommendations
Class I
1. Evaluation of familial inheritance and genetic counseling is recom-
mended as part of the assessment of patients with HCM.4-9 (Level of
Evidence: B)
2. Patients who undergo genetic testing should also undergo counsel-
ing by someone knowledgeable in the genetics of cardiovascular
disease so that results and their clinical significance can be appro-
priately reviewed with the patient.10-14 (Level of Evidence: B)
3. Screening (clinical, with or without genetic testing) is recommended
in first-degree relatives of patients with HCM.4-7,9,15,16 (Level of
Evidence: B)
4. Genetic testing for HCM and other genetic causes of unexplained
cardiac hypertrophy is recommended in patients with an atypical
clinical presentation of HCM or when another genetic condition is
suspected to be the cause.17-19 (Level of Evidence: B)
Class IIa
1. Genetic testing is reasonable in the index patient to facilitate the
identification of first-degree family members at risk for developing
HCM.5,8,15 (Level of Evidence: B)
Class IIb
1. The usefulness of genetic testing in the assessment of risk of SCD in
HCM is uncertain.20,21 (Level of Evidence: B)
Class III: No Benefit
1. Genetic testing is not indicated in relatives when the index patient
does not have a definitive pathogenic mutation.4-9,22 (Level of
Evidence: B)
2. Ongoing clinical screening is not indicated in genotype-negative rel-
atives in families with HCM.22-25 (Level of Evidence: B)
See Online Data Supplement 1 for additional data re-
garding genetic testing strategies/family screening.
2.1.1. Genotype-Positive/Phenotype-Negative Patients—
Recommendation
Class I
1. In individuals with pathogenic mutations who do not express the
HCM phenotype, it is recommended to perform serial electrocar-
diogram (ECG), transthoracic echocardiogram (TTE), and clini-
cal assessment at periodic intervals (12 to 18 months in children
and adolescents and about every 5 years in adults), based on
the patient’s age and change in clinical status.26-29 (Level of
Evidence: B)
2.2. Electrocardiography—Recommendations
Class I
1. A 12-lead ECG is recommended in the initial evaluation of patients
with HCM. (Level of Evidence: C)
2. Twenty-four–hour ambulatory (Holter) electrocardiographic mon-
itoring is recommended in the initial evaluation of patients with1308 The Journal of Thoracic and Cardiovascular SurHCM to detect ventricular tachycardia (VT) and identify patients
who may be candidates for ICD therapy.30-33 (Level of Evidence: B)
3. Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring or event recording is recommended in patients with
HCM who develop palpitations or lightheadedness.30-32 (Level of
Evidence: B)
4. A repeat ECG is recommended for patients withHCMwhen there is
worsening of symptoms. (Level of Evidence: C)
5. A 12-lead ECG is recommended every 12 to 18 months as a compo-
nent of the screening algorithm for adolescent first-degree relatives
of patients with HCM who have no evidence of hypertrophy on
echocardiography. (Level of Evidence: C)
6. A 12-lead ECG is recommended as a component of the screening al-
gorithm for first-degree relatives of patients with HCM. (Level of
Evidence: C)
Class IIa
1. Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring, repeated every 1 to 2 years, is reasonable in patients
with HCM who have no previous evidence of VT to identify pa-
tients who may be candidates for ICD therapy.33 (Level of
Evidence: C)
2. Annual 12-lead ECGs are reasonable in patients with known HCM
who are clinically stable to evaluate for asymptomatic changes in
conduction or rhythm (ie, atrial fibrillation [AF]). (Level of
Evidence: C)
Class IIb
1. Twenty-four–hour ambulatory (Holter) electrocardiographic mon-
itoringmight be considered in adults withHCM to assess for asymp-
tomatic paroxysmal AF/atrial flutter. (Level of Evidence: C)2.3. Echocardiography—Recommendations
Class I
1. ATTE is recommended in the initial evaluation of all patients with
suspected HCM.34-41 (Level of Evidence: B)
2. ATTE is recommended as a component of the screening algorithm
for family members of patients with HCM unless the family mem-
ber is genotype negative in a family with known definitive muta-
tions.42-45 (Level of Evidence: B)
3. Periodic (12 to 18 months) TTE screening is recommended for chil-
dren of patients with HCM, starting by age 12 years or earlier if
a growth spurt or signs of puberty are evident and/or when there
are plans for engaging in intense competitive sports or there is a
family history of SCD.45,46 (Level of Evidence: C)
4. Repeat TTE is recommended for the evaluation of patients with
HCM with a change in clinical status or new cardiovascular
event.47-53 (Level of Evidence: B)
5. A transesophageal echocardiogram (TEE) is recommended for the
intraoperative guidance of surgical myectomy.54-56 (Level of
Evidence: B)
6. TTE or TEE with intracoronary contrast injection of the candi-
date’s septal perforator(s) is recommended for the intraprocedural
guidance of alcohol septal ablation.57-60 (Level of Evidence: B)
7. TTE should be used to evaluate the effects of surgical myectomy or
alcohol septal ablation for obstructive HCM.60-66 (Level of
Evidence: C)
Class IIa
1. TTE studies performed every 1 to 2 years can be useful in the serial
evaluation of symptomatically stable patients with HCM to assessgery c December 2011
Gersh et al Clinical Guidelinethe degree of myocardial hypertrophy, dynamic obstruction, and
myocardial function.35,37,41 (Level of Evidence: C)
2. Exercise TTE can be useful in the detection and quantification of
dynamic LVOT obstruction in the absence of resting outflow tract
obstruction in patients with HCM.48,51,53,67,68 (Level of Evidence: B)
3. TEE can be useful if TTE is inconclusive for clinical decision mak-
ing about medical therapy and in situations such as planning for
myectomy, exclusion of subaortic membrane or mitral regurgita-
tion secondary to structural abnormalities of the mitral valve appa-
ratus, or in assessment for the feasibility of alcohol septal
ablation.54-56 (Level of Evidence: C)
4. TTE combinedwith the injection of an intravenous contrast agent is
reasonable if the diagnosis of apical HCM or apical infarction or se-
verity of hypertrophy is in doubt, particularly when other imaging
modalities such as cardiovascular magnetic resonance (CMR) are
not readily available, not diagnostic, or are contraindicated. (Level
of Evidence: C)
5. Serial TTE studies are reasonable for clinically unaffected patients
who have a first-degree relative with HCM when genetic status is
unknown. Such follow-up may be considered every 12 to 18 months
for children or adolescents fromhigh-risk families and every 5 years
for adult family members.43-46 (Level of Evidence: C)
Class III: No Benefit
1. TTE studies should not be performedmore frequently than every 12
months in patients with HCM when it is unlikely that any changes
have occurred that would have an impact on clinical decision mak-
ing. (Level of Evidence: C)
2. Routine TEE and/or contrast echocardiography is not recommen-
ded when TTE images are diagnostic of HCM and/or there is no
suspicion of fixed obstruction or intrinsic mitral valve pathology.
(Level of Evidence: C)2.4. Stress Testing—Recommendations
Class IIa
1. Treadmill exercise testing is reasonable to determine functional ca-
pacity and response to therapy in patients with HCM. (Level of
Evidence: C)
2. Treadmill testing with monitoring of an ECG and blood pressure is
reasonable for SCD risk stratification in patients with HCM.69-71
(Level of Evidence: B)
3. In patients with HCMwho do not have a resting peak instantaneous
gradient of greater than or equal to 50mmHg, exercise echocardiog-
raphy is reasonable for the detection and quantification of exercise-
induced dynamic LVOTobstruction.67,70-72 (Level of Evidence: B)2.5. Cardiac Magnetic Resonance—
Recommendations
Class I
1. CMR imaging is indicated in patients with suspected HCM when
echocardiography is inconclusive for diagnosis.73,74 (Level of
Evidence: B)
2. CMR imaging is indicated in patients with knownHCMwhen addi-
tional information that may have an impact on management or de-
cision making regarding invasive management, such as magnitude
and distribution of hypertrophy or anatomy of the mitral valve ap-
paratus or papillary muscles, is not adequately defined with echo-
cardiography.73-77 (Level of Evidence: B)The Journal of Thoracic and CarClass IIa
1. CMR imaging is reasonable in patients with HCM to define apical
hypertrophy and/or aneurysm if echocardiography is inconclu-
sive.73,75 (Level of Evidence: B)
Class IIb
1. In selected patients with known HCM, when SCD risk stratification
is inconclusive after documentation of the conventional risk factors
(Section 2.13), CMR imagingwith assessment of late gadolinium en-
hancement (LGE) may be considered in resolving clinical decision
making.78-82 (Level of Evidence: C)
2. CMR imaging may be considered in patients with LV hypertrophy
and the suspicion of alternative diagnoses to HCM, including car-
diac amyloidosis, Fabry disease, and genetic phenocopies such as
LAMP2 cardiomyopathy.83-85 (Level of Evidence: C)2.6. Detection of Concomitant Coronary Disease—
Recommendations
Class I
1. Coronary arteriography (invasive or computed tomographic imag-
ing) is indicated in patients with HCM with chest discomfort who
have an intermediate to high likelihood of coronary artery disease
(CAD) when the identification of concomitant CAD will change
management strategies. (Level of Evidence: C)
Class IIa
1. Assessment of coronary anatomy with computed tomographic angi-
ography (CTA) is reasonable for patients with HCMwith chest dis-
comfort and a low likelihood of CAD to assess for possible
concomitant CAD. (Level of Evidence: C)
2. Assessment of ischemia or perfusion abnormalities suggestive of
CAD with single photon emission computed tomography (SPECT)
or positron emission tomography (PET) myocardial perfusion im-
aging (MPI; because of excellent negative predictive value) is rea-
sonable in patients with HCM with chest discomfort and a low
likelihood of CAD to rule out possible concomitant CAD. (Level of
Evidence: C)
Class III: No Benefit
1. Routine SPECT MPI or stress echocardiography is not indicated
for detection of ‘‘silent’’ CAD-related ischemia in patients with
HCM who are asymptomatic. (Level of Evidence: C)
2. Assessment for the presence of blunted flow reserve (microvascular
ischemia) using quantitative myocardial blood flow measurements
by PET is not indicated for the assessment of prognosis in patients
with HCM. (Level of Evidence: C)2.7. Asymptomatic Patients—Recommendations
Class I
1. For patients with HCM, it is recommended that comorbidities that
may contribute to cardiovascular disease (eg, hypertension, diabe-
tes, hyperlipidemia, obesity) be treated in compliance with relevant
existing guidelines.86 (Level of Evidence: C)
Class IIa
1. Low-intensity aerobic exercise is reasonable as part of a healthy life-
style for patients with HCM.32,87 (Level of Evidence: C)diovascular Surgery c Volume 142, Number 6 1309
*Experienced operators are defined as an individual operator with a cumulative case
volume of at least 20 procedures or an individual operator who is working in a ded-
icated HCM program with a cumulative total of at least 50 procedures (Section
9.3.3).
yEligible patients are defined by all of the following:
a. Clinical: Severe dyspnea or chest pain (usually New York Heart Association
[NYHA] functional classes III or IV) or occasionally other exertional symptoms
(such as syncope or near syncope) that interfere with everyday activity or quality
of life despite optimal medical therapy.
b. Hemodynamic: Dynamic LVOT gradient at rest or with physiologic provocation
50 mm Hg associated with septal hypertrophy and systolic anterior motion
(SAM) of the mitral valve.
c. Anatomic: Targeted anterior septal thickness sufficient to perform the procedure
safely and effectively in the judgment of the individual operator.
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1. The usefulness of beta blockade and calcium channel blockers to al-
ter clinical outcome is not well established for the management of
asymptomatic patients with HCM with or without obstruction.32
(Level of Evidence: C)
Class III: Harm
1. Septal reduction therapy should not be performed for asymptomatic
adult and pediatric patients with HCMwith normal effort tolerance
regardless of the severity of obstruction.32,38 (Level of Evidence: C)
2. In patients with HCM with resting or provocable outflow tract ob-
struction, regardless of symptom status, pure vasodilators and high-
dose diuretics are potentially harmful.3,38 (Level of Evidence: C)
2.8. Pharmacologic Management—
Recommendations
Class I
1. Beta-blocking drugs are recommended for the treatment of symp-
toms (angina or dyspnea) in adult patients with obstructive or non-
obstructive HCM but should be used with caution in patients with
sinus bradycardia or severe conduction disease.3,32,36,38,88-96 (Level
of Evidence: B)
2. If low doses of beta-blocking drugs are ineffective for controlling
symptoms (angina or dyspnea) in patients with HCM, it is useful
to titrate the dose to a resting heart rate of less than 60 to 65 bpm
(up to generally accepted and recommended maximum doses of
these drugs).3,32,36,89-96 (Level of Evidence: B)
3. Verapamil therapy (starting in low doses and titrating up to 480
mg/d) is recommended for the treatment of symptoms (angina or
dyspnea) in patients with obstructive or nonobstructive HCM
who do not respond to beta-blocking drugs or who have side effects
or contraindications to beta-blocking drugs. However, verapamil
should be used with caution in patients with high gradients, ad-
vanced heart failure, or sinus bradycardia.32,36,88,97-101 (Level of
Evidence: B)
4. Intravenous phenylephrine (or another pure vasoconstricting
agent) is recommended for the treatment of acute hypotension in
patients with obstructive HCM who do not respond to fluid admin-
istration.36,102-104 (Level of Evidence: B)
Class IIa
1. It is reasonable to combine disopyramide with a beta-blocking
drug or verapamil in the treatment of symptoms (angina or dysp-
nea) in patients with obstructive HCM who do not respond to
beta-blocking drugs or verapamil alone.32,36,88,105-108 (Level of
Evidence: B)
2. It is reasonable to add oral diuretics in patients with nonobstructive
HCM when dyspnea persists despite the use of beta blockers or ve-
rapamil or their combination.41,88 (Level of Evidence: C)
Class IIb
1. Beta-blocking drugs might be useful in the treatment of symptoms
(angina or dyspnea) in children or adolescents with HCM, but pa-
tients treated with these drugs should be monitored for side effects,
including depression, fatigue, or impaired scholastic performance.
(Level of Evidence: C)
2. It may be reasonable to add oral diuretics with caution to patients
with obstructive HCM when congestive symptoms persist despite
the use of beta blockers or verapamil or their combination.32,36,88
(Level of Evidence: C)
3. The usefulness of angiotensin-converting enzyme inhibitors or an-
giotensin receptor blockers in the treatment of symptoms (angina1310 The Journal of Thoracic and Cardiovascular Suror dyspnea) in patients with HCM with preserved systolic function
is not well established, and these drugs should be used cautiously (if
at all) in patients with resting or provocable LVOT obstruction.
(Level of Evidence: C)
4. In patients withHCMwho do not tolerate verapamil or in whom ve-
rapamil is contraindicated, diltiazem may be considered. (Level of
Evidence: C)
Class III: Harm
1. Nifedipine or other dihydropyridine calcium channel-blocking
drugs are potentially harmful for treatment of symptoms (angina
or dyspnea) in patients with HCM who have resting or provocable
LVOT obstruction. (Level of Evidence: C)
2. Verapamil is potentially harmful in patients with obstructive HCM
in the setting of systemic hypotension or severe dyspnea at rest.
(Level of Evidence: C)
3. Digitalis is potentially harmful in the treatment of dyspnea in pa-
tients with HCM and in the absence of AF.3,32,36,109-111 (Level of
Evidence: B)
4. The use of disopyramide alone without beta blockers or verapamil
is potentially harmful in the treatment of symptoms (angina or
dyspnea) in patients with HCM with AF because disopyramide
may enhance atrioventricular conduction and increase the ventric-
ular rate during episodes of AF.32,40,88,112-117 (Level of Evidence: B)
5. Dopamine, dobutamine, norepinephrine, and other intravenous pos-
itive inotropic drugs are potentially harmful for the treatment of
acute hypotension in patients with obstructive HCM.3,102-104,118-121
(Level of Evidence: B)2.9. Invasive Therapies—Recommendations
Class I
1. Septal reduction therapy should be performed only by experienced
operators* in the context of a comprehensive HCM clinical pro-
gram and only for the treatment of eligible patients with severe
drug-refractory symptoms and LVOT obstruction.y122 (Level of
Evidence: C)
Class IIa
1. Consultation with centers experienced in performing both surgical
septal myectomy and alcohol septal ablation is reasonable when dis-
cussing treatment options for eligible patients with HCM with se-
vere drug-refractory symptoms and LVOT obstruction. (Level of
Evidence: C)
2. Surgical septal myectomy, when performed in experienced centers,
can be beneficial and is the first consideration for the majority of el-
igible patients with HCM with severe drug-refractory symptoms
and LVOT obstruction.60,64,65,123-125 (Level of Evidence: B)gery c December 2011
Gersh et al Clinical Guideline3. Surgical septal myectomy, when performed at experienced centers,
can be beneficial in symptomatic children with HCM and severe
resting obstruction (>50 mm Hg) for whom standard medical ther-
apy has failed.126 (Level of Evidence: C)
4. When surgery is contraindicated or the risk is considered unaccept-
able because of serious comorbidities or advanced age, alcohol sep-
tal ablation, when performed in experienced centers, can be
beneficial in eligible adult patients with HCM with LVOT obstruc-
tion and severe drug-refractory symptoms (usually NYHA func-
tional classes III or IV).60,62,127-131 (Level of Evidence: B)
Class IIb
1. Alcohol septal ablation, when performed in experienced centers,
may be considered as an alternative to surgical myectomy for eligi-
ble adult patients with HCMwith severe drug-refractory symptoms
and LVOTobstruction when, after a balanced and thorough discus-
sion, the patient expresses a preference for septal abla-
tion.62,123,128,130,131 (Level of Evidence: B)
2. The effectiveness of alcohol septal ablation is uncertain in patients
with HCM with marked (ie, >30 mm) septal hypertrophy, and
therefore the procedure is generally discouraged in such patients.
(Level of Evidence: C)
Class III: Harm
1. Septal reduction therapy should not be done for adult patients with
HCM who are asymptomatic with normal exercise tolerance or
whose symptoms are controlled or minimized on optimal medical
therapy. (Level of Evidence: C)
2. Septal reduction therapy should not be done unless performed as
part of a program dedicated to the longitudinal and multidisciplin-
ary care of patients with HCM. (Level of Evidence: C)
3. Mitral valve replacement for relief of LVOTobstruction should not
be performed in patients with HCM in whom septal reduction ther-
apy is an option. (Level of Evidence: C)
4. Alcohol septal ablation should not be done in patients with HCM
with concomitant disease that independently warrants surgical cor-
rection (eg, coronary artery bypass grafting for CAD, mitral valve
repair for ruptured chordae) in whom surgical myectomy can be
performed as part of the operation. (Level of Evidence: C)
5. Alcohol septal ablation should not be done in patientswithHCMwho
are less than 21 years of age and is discouraged in adults less than 40
years of age if myectomy is a viable option. (Level of Evidence: C)
See Online Data Supplement 2 for additional data re-
garding invasive therapies.*Characterized by systolic dysfunction (EF50%), often associated with LV remod-
eling, including cavity enlargement and wall thinning, and because of diffuse myo-
cardial scarring.2.10. Pacing—Recommendations
Class IIa
1. In patients with HCM who have had a dual-chamber device im-
planted for non-HCM indications, it is reasonable to consider a trial
of dual-chamber atrial-ventricular pacing (from the right ventricu-
lar apex) for the relief of symptoms attributable to LVOT obstruc-
tion.132-135 (Level of Evidence: B)
Class IIb
1. Permanent pacingmay be considered inmedically refractory symp-
tomatic patients with obstructive HCM who are suboptimal candi-
dates for septal reduction therapy.132-136 (Level of Evidence: B)
Class III: No Benefit
1. Permanent pacemaker implantation for the purpose of reducing
gradient should not be performed in patients with HCM who areThe Journal of Thoracic and Carasymptomatic or whose symptoms are medically controlled.136-138
(Level of Evidence: C)
2. Permanent pacemaker implantation should not be performed as
a first-line therapy to relieve symptoms in medically refractory
symptomatic patients with HCM and LVOT obstruction who are
candidates for septal reduction.136-138 (Level of Evidence: B)
See Online Data Supplement 3 for additional data re-
garding pacing.
2.11. Patients With LV Systolic Dysfunction—
Recommendations
Class I
1. Patients with nonobstructive HCM who develop systolic dysfunc-
tion with an ejection fraction (EF) less than or equal to 50% should
be treated according to evidence-based medical therapy for adults
with other forms of heart failure with reduced EF, including
angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, beta blockers, and other indicated drugs.49,139 (Level of
Evidence: B)
2. Other concomitant causes of systolic dysfunction (such as CAD)
should be considered as potential contributors to systolic dysfunc-
tion in patients with HCM. (Level of Evidence: C)
Class IIb
1. ICD therapy may be considered in adult patients with advanced (as
defined by NYHA functional class III or IV heart failure) nonob-
structive HCM, on maximal medical therapy, and EF less than or
equal to 50%, who do not otherwise have an indication for an
ICD.49 (Level of Evidence: C)
2. For patients with HCMwho develop systolic dysfunction, it may be
reasonable to reassess the use of negative inotropic agents previ-
ously indicated, for example, verapamil, diltiazem, or disopyra-
mide, and to consider discontinuing those therapies. (Level of
Evidence: C)2.12. Selection of Patients for Heart
Transplantation—Recommendations
Class I
1. Patients with advanced heart failure (end-stage*) and nonob-
structive HCM not otherwise amenable to other treatment inter-
ventions, with EF less than 50% (or occasionally with preserved
EF), should be considered for heart transplantation.49,140 (Level
of Evidence: B)
2. Symptomatic children with HCM with restrictive physiology who
are not responsive to or appropriate candidates for other therapeu-
tic interventions should be considered for heart transplanta-
tion.141,142 (Level of Evidence: C)
Class III: Harm
1. Heart transplantation should not be performed in mildly symptom-
atic patients of any age with HCM. (Level of Evidence: C)
2.13. SCD Risk Stratification—Recommendations
Class Idiovascular Surgery c Volume 142, Number 6 1311
FIGURE 1. Indications for ICDs in HCM. *SCD riskmodifiers include es-
tablished risk factors and emerging risk modifiers (Section 9.4.2).BP, Blood
pressure; ICD, implantable cardioverter-defibrillator; LV, left ventricular;
SCD, sudden cardiac death; SD, sudden death; VT, ventricular tachycardia.
Clinical Guideline Gersh et al1. All patients with HCM should undergo comprehensive SCD risk
stratification at initial evaluation to determine the presence of the
following:30,31,143-152 (Level of Evidence: B)
a. A personal history for ventricular fibrillation, sustained VT, or
SCD events, including appropriate ICD therapy for ventricular
tachyarrhythmias.y
b. A family history for SCD events, including appropriate ICD
therapy for ventricular tachyarrhythmias.y
c. Unexplained syncope.
d. Documented nonsustained ventricular tachycardia (NSVT) de-
fined as 3 or more beats at greater than or equal to 120 bpm
on ambulatory (Holter) ECG.
e. Maximal LV wall thickness greater than or equal to 30 mm.
Class IIa
1. It is reasonable to assess blood pressure response during exercise as
part of SCD risk stratification in patients with HCM.30,71,149 (Level
of Evidence: B)
2. SCD risk stratification is reasonable on a periodic basis (every 12
to 24 months) for patients with HCM who have not undergone
ICD implantation but would otherwise be eligible in the event
that risk factors are identified (12 to 24 months). (Level of
Evidence: C)
Class IIb
1. The usefulness of the following potential SCD risk modifiers is un-
clear but might be considered in selected patients with HCM for
whom risk remains borderline after documentation of conventional
risk factors:
a. CMR imaging with LGE.78,82 (Level of Evidence: C)
b. Double and compound mutations (ie, >1). (Level of Evi-
dence: C)
c. Marked LVOT obstruction.30,48,51,149 (Level of Evidence: B)
Class III: Harm
1. Invasive electrophysiologic testing as routine SCD risk stratifica-
tion for patients with HCM should not be performed. (Level of
Evidence: C)
See Online Data Supplement 4 for additional data re-
garding SCD risk stratification.
2.14. SelectionofPatients for ICDs—Recommendations
Class I
1. The decision to place an ICD in patients with HCM should include
application of individual clinical judgment, as well as a thorough
discussion of the strength of evidence, benefits, and risks to allow
the informed patient’s active participation in decision making
(Figure 1).144,150,153,154 (Level of Evidence: C)
2. ICD placement is recommended for patients with HCM with prior
documented cardiac arrest, ventricular fibrillation, or hemodynam-
ically significant VT.145,146,148,150 (Level of Evidence: B)
Class IIa
1. It is reasonable to recommend an ICD for patients with HCMwith:yAppropriate ICD discharge is defined as ICD therapy triggered by VTor ventricular
fibrillation, documented by stored intracardiac electrogram or cycle-length data, in
conjunction with the patient’s symptoms immediately before and after device dis-
charge.
1312 The Journal of Thoracic and Cardiovascular Sura. Sudden death presumably caused by HCM in 1 or more first-
degree relatives.155 (Level of Evidence: C)
b. A maximum LV wall thickness greater than or equal to 30
mm.147,156-158 (Level of Evidence: C)
c. One or more recent, unexplained syncopal episodes.152 (Level of
Evidence: C)
2. An ICD can be useful in select patients with NSVT (particularly
those<30 years of age) in the presence of other SCD risk factors
or modifiers.z33,144 (Level of Evidence: C)
3. An ICD can be useful in select patients withHCMwith an abnormal
blood pressure response with exercise in the presence of other SCD
risk factors or modifiers.z70,71,149 (Level of Evidence: C)
4. It is reasonable to recommend an ICD for high-risk children with
HCM, based on unexplained syncope, massive LV hypertrophy, or
family history of SCD, after taking into account the relatively
high complication rate of long-term ICD implantation. (Level of
Evidence: C)
Class IIb
1. The usefulness of an ICD is uncertain in patients with HCM with
isolated bursts of NSVT when in the absence of any other SCD
risk factors or modifiers.z,144 (Level of Evidence: C)
2. The usefulness of an ICD is uncertain in patients with HCM with an
abnormal blood pressure response with exercise when in the absence
of anyother SCDrisk factors ormodifiers,z particularly in the presence
of significant outflow obstruction.70,71,149 (Level of Evidence: C)zSCD risk modifiers are discussed in Section 9.4.2.
gery c December 2011
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TABLE 2. Recommendations for the acceptability of recreational
(noncompetitive) sports activities and exercise in patients with HCM*
Intensity level Eligibility scale for HCMy
High
Basketball (full court) 0
Basketball (half court) 0
Body buildingz 1
Gymnastics 2
Ice hockeyz 0Class III: Harm
1. ICD placement as a routine strategy in patients with HCM without
an indication of increased risk is potentially harmful. (Level of
Evidence: C)
2. ICD placement as a strategy to permit patients with HCM to partic-
ipate in competitive athletics is potentially harmful. (Level of
Evidence: C)
3. ICD placement in patients who have an identified HCM genotype in
the absence of clinical manifestations of HCM is potentially harm-
ful. (Level of Evidence: C)
Racquetball/squash 0
Rock climbingz 1
Running (sprinting) 0
Skiing (downhill)z 2
Skiing (cross-country) 2
Soccer 0
Tennis (singles) 0
Touch (flag) football 1
Windsurfingx 1
Moderate
Baseball/softball 2
Biking 4
Hiking 3
Modest hiking 4
Motorcyclingz 3
Jogging 3
Sailingx 3
Surfingx 22.15. Selection of ICD Device Type—
Recommendations
Class IIa
1. In patients with HCM who meet indications for ICD implanta-
tion, single-chamber devices are reasonable in younger patients
without a need for atrial or ventricular pacing.159-162 (Level of
Evidence: B)
2. In patients with HCM who meet indications for ICD implantation,
dual-chamber ICDs are reasonable for patients with sinus brady-
cardia and/or paroxysmal AF.159 (Level of Evidence: C)
3. In patients with HCM who meet indications for ICD implantation,
dual-chamber ICDs are reasonable for patients with elevated rest-
ing outflow gradients greater than 50 mm Hg and significant heart
failure symptoms who may benefit from right ventricular pacing
(most commonly, but not limited to, patients >65 years of
age).136-138,159 (Level of Evidence: B)Swimming (laps)x 5
Tennis (doubles) 4
Treadmill/stationary bicycle 5
Weightlifting (free weights)z,k 1
Low
Bowling 5
Brisk walking 5
Golf 5
Horseback ridingz 3
Scuba divingx 0
Skating{ 5
Snorkelingx 5
Weights (nonfree weights) 4
*Recreational sports are categorized according to high, moderate, and low levels of ex-
ercise and graded on a relative scale (from 0 to 5) for eligibility, with 0 to 1 indicating
generally not advised or strongly discouraged; 4 to 5, probably permitted; and 2 to 3, in-
termediate and to be assessed clinically on an individual basis. The designations of high,
moderate, and low levels of exercise are equivalent to an estimated>6, 4 to 6, and<42.16. Participation in Competitive or Recreational
Sports and Physical Activity—Recommendations
Class IIa
1. It is reasonable for patients with HCM to participate in low-
intensity competitive sports (eg, golf and bowling).163,164 (Level of
Evidence: C)
2. It is reasonable for patients with HCM to participate in a range of
recreational sporting activities as outlined in Table 2.87 (Level of
Evidence: C)
Class III: Harm
1. Patients with HCM should not participate in intense competitive
sports regardless of age, sex, race, presence or absence of LVOTob-
struction, prior septal reduction therapy, or implantation of a cardi-
overter-defibrillator for high-risk status.163-169 (Level of Evidence: C)metabolic equivalents, respectively. yAssumes absence of laboratory DNA genotyping
data; therefore, limited to clinical diagnosis. zThese sports involve the potential for
traumatic injury, which should be taken into consideration for individuals with a risk
for impaired consciousness. xThe possibility of impaired consciousness occurring dur-
ing water-related activities should be taken into account with respect to the individual
patient’s clinical profile. kRecommendations generally differ from those for weight-
training machines (nonfree weights), based largely on the potential risks of traumatic
injury associated with episodes of impaired consciousness during bench-press maneu-
vers; otherwise, the physiologic effects of all weight-training activities are regarded as
similar with respect to the present recommendations. {Individual sporting activity not
associated with the team sport of ice hockey. Adapted with permission from Maron
et al.872.17. Management of AF—Recommendations
Class I
1. Anticoagulation with vitamin K antagonists (ie, warfarin, to an in-
ternational normalized ratio of 2.0 to 3.0) is indicated in patients
with paroxysmal, persistent, or chronic AF and HCM.170-172
(Anticoagulation with direct thrombin inhibitors [ie, dabigatranx]
may represent another option to reduce the risk of thromboembolic
events, but data for patients with HCM are not available.173) (Level
of Evidence: C)xDabigatran should not be used in patients with prosthetic valves, hemodynamically
significant valve disease, advanced liver failure, or severe renal failure (creatinine
clearance<15 mL/min).173
The Journal of Thoracic and Car2. Ventricular rate control in patients with HCMwith AF is indicated
for rapid ventricular rates and can require high doses of beta antag-
onists and nondihydropyridine calcium channel blockers.170,172
(Level of Evidence: C)diovascular Surgery c Volume 142, Number 6 1313
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1. Disopyramide (with ventricular rate-controlling agents) and amio-
darone are reasonable antiarrhythmic agents for AF in patients
with HCM.170,174 (Level of Evidence: B)
2. Radiofrequency ablation for AF can be beneficial in patients with
HCMwho have refractory symptoms or who are unable to take an-
tiarrhythmic drugs.175-179 (Level of Evidence: B)
3. Maze procedure with closure of left atrial appendage is reasonable
in patients with HCM with a history of AF, either during septal
myectomy or as an isolated procedure in selected patients. (Level
of Evidence: C)
Class IIb
1. Sotalol, dofetilide, and dronedarone might be considered alterna-
tive antiarrhythmic agents in patients with HCM, especially in
those with an ICD, but clinical experience is limited. (Level of
Evidence: C)2.18. Pregnancy/Delivery—Recommendations
Class I
1. In women with HCM who are asymptomatic or whose symptoms
are controlled with beta-blocking drugs, the drugs should be
continued during pregnancy, but increased surveillance for fetal
bradycardia or other complications is warranted.43,44,181 (Level of
Evidence: C)
2. For patients (mother or father) with HCM, genetic counseling is in-
dicated before planned conception. (Level of Evidence: C)
3. In women with HCM and resting or provocable LVOT obstruction
greater than or equal to 50 mm Hg and/or cardiac symptoms not
controlled by medical therapy alone, pregnancy is associated with
increased risk, and these patients should be referred to a high-
risk obstetrician. (Level of Evidence: C)
4. The diagnosis of HCM among asymptomatic women is not consid-
ered a contraindication for pregnancy, but patients should be care-
fully evaluated in regard to the risk of pregnancy. (Level of
Evidence: C)
Class IIa
1. For women with HCM whose symptoms are controlled (mild to
moderate), pregnancy is reasonable, but expert maternal/fetal med-
ical specialist care, including cardiovascular and prenatal monitor-
ing, is advised. (Level of Evidence: C)
Class III: Harm
1. For women with advanced heart failure symptoms and HCM, preg-
nancy is associated with excess morbidity/mortality. (Level of Evi-
dence: C)3. PREVALENCE/NOMENCLATURE/
DIFFERENTIAL DIAGNOSIS
3.1. Prevalence
HCM is a common genetic cardiovascular disease. In ad-
dition, HCM is a global disease,182 with epidemiological
studies from several parts of the world183 reporting a similar
prevalence of LV hypertrophy, the quintessential phenotype
of HCM, to be about 0.2% (ie, 1:500) in the general1314 The Journal of Thoracic and Cardiovascular Surpopulation, which is equivalent to at least 600,000 people
affected in the United States.184
3.1.1. Clinical Definition and Differential Diagnosis
HCM is the preferred nomenclature to describe this
disease,185 although confusion over the names used to
characterize this entity has arisen over the years in part
because one third of patients have no obstruction either at
rest or with physiologic provocation.67 The generally ac-
cepted definition of HCM is a disease state characterized
by unexplained LV hypertrophy associated with nondilated
ventricular chambers in the absence of another cardiac or
systemic disease that itself would be capable of producing
the magnitude of hypertrophy evident in a given
patient,32,38,184-187 with the caveat that patients who are
genotype positive may be phenotypically negative without
overt hypertrophy.188,189 Clinically, HCM is usually
recognized by a maximal LV wall thickness 15 mm. In
the case of children, increased LV wall thickness is
defined as wall thickness 2 standard deviations above
the mean (z score 2) for age, sex, or body size.
However, it should be underscored that in principle, any
degree of wall thickness is compatible with the presence
of the HCM genetic substrate. Furthermore, although
a myriad of patterns and distribution of LV hypertrophy
(including diffuse and marked) have been reported in
HCM,37,76,190 about one third of patients have largely
segmental wall thickening involving only a small portion
of the left ventricle, and indeed, such patients with HCM
usually have normal calculated LV mass.76
Differential diagnosis of HCM and other cardiac condi-
tions (with LV hypertrophy) may arise, most commonly
with hypertensive heart disease and the physiologic remod-
eling associated with athletic training (‘‘athlete’s
heart’’),191-195 usually when maximum wall thickness is
in the modest range of 13 to 15 mm.
These important distinctions are often resolved by nonin-
vasive markers, including sarcomeric mutations or family
history of HCM, LV cavity dimension, diastolic function,
pattern of LV hypertrophy, or short deconditioning pe-
riods.191-195
It is evident that metabolic or infiltrative storage disorders
with LV hypertrophy in babies, older children, and young
adults can mimic clinically diagnosed HCM (attributable to
sarcomeric protein mutations), for example, conditions
such as mitochondrial disease,196,197 Fabry disease,198 or
storage diseases caused by mutations in the genes encoding
the g-2-regulatory subunit of the adenosine monophosphate
(AMP)-activated protein kinase (PRKAG2) or the X-linked
lysosome-associated membrane protein gene (LAMP2; Da-
non disease).4,199-201 Use of the term HCM is not
appropriate to describe these and other patients with LV
hypertrophy that occurs in the context of a multisystem
disorder202-206 (Figure 2). In addition, differential diagnosisgery c December 2011
FIGURE 2. Summary of the nomenclature that distinguishes HCM from
other genetic diseases associated with LV hypertrophy. *At this time the
overwhelming evidence links the clinical diagnosis of HCM with a variety
of genes encoding protein components of the cardiac sarcomere. However,
it is possible that in the future other nonsarcomeric (but also nonmetabolic)
genes may prove to cause HCM. yAn example is Noonan syndrome with
cardiomyopathy. Modified with permission from Maron et al.187
Gersh et al Clinical Guideline
FIGURE 3. Prognosis profiles for HCM and targets for therapy. AF, Atrial
fibrillation. Modified with permission from Maron et al.32of HCM may require distinction from dilated cardiomyopa-
thy when HCM presents in the end stage.49
3.1.2. Impact of Genetics
On the basis of the genotype-phenotype data available at
this time, HCM is regarded here as a disease entity caused
by autosomal dominant mutations in genes encoding pro-
tein components of the sarcomere and its constituent myo-
filament elements.43,199,207,208 Intergenetic diversity is
compounded by considerable intragene heterogeneity,
with>1400 mutations identified among at least 8 genes.
The current weight of evidence supports the view that the
vast majority of genes and mutations responsible for
clinically diagnosed HCM encode proteins within and
associated with the sarcomere, accounting in large
measure for those patients described in the voluminous
amount of HCM literature published over 50
years.43,199,207,208
3.1.3. HCM Centers
The writing committee considers it important to empha-
size that HCM is a complex disease entity with a broad (and
increasing) clinical and genetic spectrum.38 Although HCM
is one of the most common forms of genetic heart disease
and relatively common in the general population,184 this
disease entity is infrequent in general clinical practice,
with most cardiologists responsible for the care of only
a few patients with HCM.209 This principle has led to an
impetus for establishing clinical programs of excellence—
usually within established centers—in which cardiovascu-
lar care is focused on the management of HCM (ie,
‘‘HCM centers’’).209,210The Journal of Thoracic and Car4. CLINICAL COURSE AND NATURAL HISTORY,
INCLUDING ABSENCE OF COMPLICATIONS
HCM is a heterogeneous cardiac disease with a diverse
clinical presentation and course, presenting in all age
groups from infancy to the very elderly.32,38,49,51 Most
affected individuals probably achieve a normal life
expectancy without disability or the necessity for major
therapeutic interventions.211-214 On the other hand, in
some patients, HCM is associated with disease
complications that may be profound, with the potential to
result in disease progression or premature
death.32,38,49,51,147,156 When the disease does result in
significant complications, there are 3 relatively discrete
but not mutually exclusive pathways of clinical
progression (Figure 3):
1. SCD due to unpredictable ventricular tachyarrhyth-
mias, most commonly in asymptomatic patients
<35 years of age50,144,147,150,153,154,156,166,168,215
(including competitive athletes).166,168
2. Heart failure characterized by exertional dyspnea
(with or without chest pain) thatmay be progressive.49
3. AF, also associated with various degrees of heart fail-
ure172 and an increased risk of systemic thromboem-
bolism and stroke.
The natural history of HCM can be altered by a number
of therapeutic interventions: ICDs for secondary or pri-
mary prevention of sudden death in patients with risk fac-
tors150,153,154; drugs appropriate to control heart failure
symptoms (principally those of exertional dyspnea and
chest discomfort),32,38 surgical septal myectomy64 or al-
cohol septal ablation60 for progressive and drug-
refractory heart failure caused by LVOT obstruction;
heart transplantation for systolic (or less frequently, in-
tractable diastolic) dysfunction associated with severe un-
relenting symptoms49; and drug therapy or possibly
radiofrequency ablation or surgical maze procedure for
AF.175,178,179diovascular Surgery c Volume 142, Number 6 1315
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The pathophysiology of HCM is complex and consists of
multiple interrelated abnormalities, including LVOT ob-
struction, diastolic dysfunction, mitral regurgitation, myo-
cardial ischemia, and arrhythmias.38,40,41 It is clinically
important to distinguish between the obstructive and
nonobstructive forms of HCM because management
strategies are largely dependent on the presence or
absence of symptoms caused by obstruction.5.1. LVOT Obstruction
The original observations by Brock216 and Braunwald
et al3 emphasized the functional subvalvular LVOT gradi-
ent, which was highly influenced by alterations in the
load and contractility of the left ventricle. The clinical sig-
nificance of the outflow tract gradient has periodically been
controversial,217-220 but careful studies have shown
definitively that true mechanical obstruction to outflow
does occur.40,41 For HCM, it is the peak instantaneous LV
outflow gradient rather than the mean gradient that
influences treatment decisions (Table 3).
Outflow obstruction usually occurs in HCM by virtue of
mitral valve SAM and mitral-septal contact. Muscular ob-
struction can also be present in the midcavitary region, oc-
casionally because of hypertrophied papillary muscles
abutting the septum223 or anomalous papillary muscle inser-
tion into the anterior mitral leaflet.224
Obstruction to LV outflow is dynamic, varying with
loading conditions and contractility of the ventricle.3 In-
creased myocardial contractility, decreased ventricular
volume, or decreased afterload increases the degree of
subaortic obstruction. Patients may have little or no ob-
struction of the LVOT at rest but can generate large
LVOT gradients under conditions such as exercise, the
strain phase of the Valsalva maneuver, or during pharma-
cologic provocation.40,41 There is often large spontaneous
variation in the severity of the gradient during day-to-day
activities or even with food or alcohol intake225; exacer-
bation of symptoms during the postprandial period isTABLE 3. Definitions of dynamic left ventricular outflow tract
obstruction
Hemodynamic
State Conditions Outflow gradient*
Basal obstruction Rest 30 mm Hgy
Nonobstructive Rest <30 mm Hg
Physiologically provoked <30 mm Hg
Labile obstruction Rest <30 mm Hgy
Physiologically provoked 30 mm Hgy
*Either the peak instantaneous continuous wave Doppler gradient or the peak-to-
peak cardiac catheterization gradient, which are equivalent in hypertrophic cardio-
myopathy.221,222 yGradients 50 mm Hg either at rest or with provocation are con-
sidered the threshold for septal reduction therapy in severely symptomatic patients.
1316 The Journal of Thoracic and Cardiovascular Surcommon. Importantly, it has been well established that
LVOT obstruction contributes to the debilitating heart
failure–related symptoms that may occur in HCM,40,41
and is also a major determinant of outcome.51
The presence and magnitude of outflow obstruction are
usually assessed with 2-dimensional echocardiography
and continuous wave Doppler. Combining exercise testing
with Doppler echocardiography is useful in identifying
the presence of physiologically provocable LVOT obstruc-
tion and is particularly helpful in patients with symptoms
during routine physical activities who do not manifest out-
flow obstruction at rest.67 Provocation with dobutamine in-
fusion during Doppler echocardiography is no longer
recommended as a strategy to induce outflow gradients in
HCM.6. DIAGNOSIS
The clinical diagnosis of HCM is conventionally made
with cardiac imaging, at present most commonly with 2-
dimensional echocardiography and increasingly with
CMR. Morphologic diagnosis is based on the presence
of a hypertrophied and nondilated left ventricle in the ab-
sence of another cardiac or systemic disease capable of
producing the magnitude of hypertrophy evident in a pa-
tient (usually 15 mm in an adult or the equivalent rel-
ative to body surface area in children). Genetic testing,
which is now commercially available, is a powerful strat-
egy for definitive diagnosis of affected genetic status and
is currently used most effectively in the identification of
affected relatives in families known to have HCM.
HCM is caused by an autosomal dominant mutation in
genes that encode sarcomere proteins or sarcomere-
associated proteins. The most vigorous evidence indicates
that 8 genes are known to definitively cause HCM: beta
myosin heavy chain, myosin binding protein C, troponin
T, troponin I, alpha tropomyosin, actin, regulatory light
chain, and essential light chain.43,186,187,199,207,208 In
addition, actinin and myozenin are associated with less
definitive evidence for causing HCM. At this time there is
inconclusive evidence to support other genes causing
HCM,7,9,226,227 but research is ongoing.6,228 A single
mutation in 1 of the 2 alleles (or copies) of a gene is
sufficient to cause HCM; however, 5% of patients with
HCM have 2 mutations in the same or different
genes.23,229
Genetic and/or clinical screening of all first-degree fam-
ily members of patients with HCM is important to identify
those with unrecognized disease. On the basis of family his-
tory, clinical screening, and pedigree analyses, the pattern
of inheritance is ascertained to identify and counsel rela-
tives at risk.14 Because familial HCM is a dominant disor-
der, the risk that an affected patient will transmit disease
to each offspring is 50%. When a pathogenic mutation isgery c December 2011
TABLE 4. Proposed clinical screening strategies with
echocardiography (and 12-lead ECG) for detection of hypertrophic
cardiomyopathy with left ventricular hypertrophy in families*
Age<12 y
Optional unless
Malignant family history of premature death from HCM or other
adverse complications
Patient is a competitive athlete in an intense training program
Onset of symptoms
Other clinical suspicion of early LV hypertrophy
Age 12 to 18–21 yy
Every 12–18 mo
Age>18–21 y
At onset of symptoms or at least every 5 y. More frequent intervals are
appropriate in families with a malignant clinical course or late-onset
HCM
ECG, Electrocardiogram; HCM, hypertrophic cardiomyopathy; LV, left ventricular.
*When pathologic mutations are not identified or genetic testing is either ambiguous
or not performed. yAge range takes into consideration individual variability in achiev-
ing physical maturity and in some patients may justify screening at an earlier age. Ini-
tial evaluation should occur no later than early pubescence.233
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ily member can be readily ascertained.
Because unrelated patients with HCM will have different
mutations, a comprehensive sequence-based analysis of all
HCM genes is necessary to define the pathogenic (eg, dis-
ease causing) mutation in an index patient. Experienced
clinical laboratories identify the pathogenic HCMmutation
in approximately 60% to 70% of patients with a positive
family history and approximately 10% to 50% of patients
without a family history.6,15 Genetic testing may identify
a pathogenic mutation (eg, analysis defines a sequence
variant known to cause HCM) or a ‘‘likely pathogenic’’
mutation, a DNA variant that was previously unknown as
a cause of HCM but has molecular characteristics that are
similar to recognized HCM mutations. Genetic testing
may also identify ‘‘variants of uncertain significance.’’
Studies suggest that the presence of>1 HCM-associated
sarcomere mutation is associated with greater severity of
disease.23,24,230,231
When genetic testing reveals a mutation in the index pa-
tient, ascertainment of genetic status in first-degree relatives
can be predictive of risk for developing HCM.18 Genetic
counseling should precede genetic testing of family mem-
bers.14 Relatives with overt HCM will have the same path-
ogenic HCM mutation as the index patient. Pathogenic
mutations may also be identified in other relatives with un-
known clinical status. These mutation carriers should be
evaluated by physical examination, electrocardiography,
and 2-dimensional echocardiography, and if HCM is identi-
fied, these individuals should undergo risk stratification
(Section 2.13). Mutation carriers without evidence of
HCM (genotype positive/phenotype negative) are at consid-
erable risk for future development of HCM, and guidelines
to evaluate these individuals are discussed below.188,189
Mutation-negative family members and their descendents
have no risk for developing HCM and do not need further
evaluation. Information from genotyping may help define
clinical manifestations and outcomes in specific families
with HCM (Table 4).7-9,18,20-22,232
6.1. Cardiovascular Magnetic Resonance
CMR provides superior spatial resolution with sharp con-
trast between blood and myocardium, as well as tomo-
graphic imaging of the entire LV myocardium and
therefore the opportunity to more accurately characterize
the presence and distribution of LV hypertrophy in HCM.
Two-dimensional echocardiography has demonstrated
the heterogeneity of the hypertrophic phenotype in patients
with HCM, particularly with regard to distribution of LV
hypertrophy and mechanisms of outflow obstruc-
tion.32,38,67,76,190,220,234 However, there remain patients in
whom the diagnosis of HCM is suspected but the
echocardiogram is inconclusive, mostly because of
suboptimal imaging from poor acoustic windows or whenThe Journal of Thoracic and Carhypertrophy is localized to regions of the LV myocardium
not well visualized by echocardiography.76 In 1 study, 6%
of patients with suspected HCM were identified with in-
creased LV wall thickness (predominantly in the anterolat-
eral wall) by CMR but not by echocardiography.74,76,77 In
addition, hypertrophy confined to the apex (ie, apical
HCM) may be difficult to visualize with
echocardiography but is evident with CMR.73,75
Furthermore, CMR can more readily detect the presence
of apical aneurysms (particularly when small). The latter
has potential implications for management with ICDs
and/or anticoagulation. The magnitude of LV wall
thickening may be underestimated by echocardiography
compared with CMR, particularly when this region
involves the anterolateral free wall,76,77 and therefore
CMR may identify high-risk status on the basis of massive
hypertrophy. Accurate characterization of the HCM pheno-
type by CMR may also be useful in management decisions
for invasive therapies (septal myectomy or alcohol septal
ablation) by more precisely defining the location and mag-
nitude of hypertrophy, as well as characterizing the mitral
and submitral apparatus and papillary muscles.235,236
The opportunity for contrast-enhanced CMR with LGE
to identify areas of myocardial fibrosis in patients with
HCM has been the subject of a growing litera-
ture.79-81,237,238 Although patients with the end-stage phe-
notype almost universally demonstrate such findings,49
patients with HCM with preserved systolic function may
also have areas of LGE.79-81 Importantly, patients with
HCM with evidence of LGE on CMR imaging tend to
have more markers of risk of SCD, such as NSVT on
Holter monitoring, than patients without LGE.78,80diovascular Surgery c Volume 142, Number 6 1317
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placement myocardial fibrosis) could represent a substrate
for the generation of malignant ventricular tachyarrhyth-
mias in HCM. Several studies have addressed this issue
and have reported either trends in such a direction or signif-
icant associations between the presence of LGE (not extent)
and cardiac outcome events.81,239 However, there is
insufficient evidence at this time to support a significant
association between the extent of LGE and outcome.
Nonetheless, the present data would support a potential
role of LGE as an arbitrator in decision making for
primary prevention ICDs in patients in whom risk status
remains uncertain after assessment of conventional risk
markers.79,807. CONCOMITANT CORONARY DISEASE
Chest discomfort is a common symptom in patients with
HCM. A key management issue revolves around whether
the discomfort may be caused by concomitant epicardial
obstructive CAD with inducible ischemia or a consequence
of microvascular dysfunction.38 Concomitant presence of
CAD in patients with HCM identifies a higher risk for
adverse outcomes and potential candidates for
revascularization.240,241
Myocardial bridging of the left anterior descending cor-
onary artery is a frequent component of phenotypically ex-
pressed HCM and more common than in other diseases with
or without LV hypertrophy. Although it has been suggested
that ischemia secondary to bridging could be a potential
mechanism for sudden death in HCM,242 there is no consis-
tent evidence to support this hypothesis in either adults or
children.243,2448. CHOICE OF IMAGING MODALITY
8.1. Invasive Coronary Arteriography
Invasive coronary arteriography is indicated in patients
with HCM when knowledge of these features will impor-
tantly influence management strategies. Coronary arteriog-
raphy should be undertaken before alcohol septal ablation
in order to define the anatomy of the septal perforators
and exclude obstructive coronary stenoses.8.2. Noninvasive CTA
Although there are no published data specifically assess-
ing the performance characteristics of CTA for document-
ing the presence or absence of epicardial CAD in HCM,
there is no reason to believe that performance of the test
should differ in patients with HCM. A high negative predic-
tive value to exclude CAD is particularly consistent in the
literature.1318 The Journal of Thoracic and Cardiovascular Sur8.3. Single Photon Emission Computed Tomography
Myocardial Perfusion Imaging
Stress SPECTMPI in patients with HCMwill often dem-
onstrate reversible or fixed perfusion defects consistent with
ischemia or infarction, respectively, even in the absence of
epicardial CAD.245,246 Several lines of evidence support
that these defects, even in the absence of symptoms,
represent true flow abnormalities and possibly ‘‘silent’’
ischemia.247
Fixed defects may also be seen with SPECT MPI, a find-
ing consistent with infarction. These patients will often
have the ‘‘end-stage’’ clinical phenotype with reduced
EF245 and likely correspond to patients who demonstrate
LGE in CMR studies.49
8.4. Positron Emission Tomography
PET imaging has been used in patients with HCM to
study myocardial blood flow, as well as myocardial me-
tabolism. In patients with HCM with normal coronary
arteries, myocardial perfusion PET studies have shown
that although resting myocardial blood flow may be sim-
ilar to normal control subjects, the augmentation of
blood flow with vasodilation, for example, dipyridamole,
may be significantly blunted.248-251 However, the
quantitative PET techniques used in these studies are
not part of routine clinical practice, and the
management implications of identifying abnormalities
in flow reserve are unresolved.
8.5. Stress Echocardiography
There are no published studies addressing the perfor-
mance characteristics of stress echocardiography to detect
or exclude CAD in patients with HCM. Patients with
HCM have heterogeneous wall-thickness patterns, and
wall motion at rest may appear abnormal in regions of hy-
pertrophied myocardium. Therefore, stress echocardiogra-
phy to detect or rule out CAD may be unreliable in HCM
but may be useful to document the presence or magnitude
of outflow tract obstruction generated by exercise67
(Section 5.1).
9. MANAGEMENT OF HCM
Treatment of patients with HCM requires a thorough un-
derstanding of the complex, diverse pathophysiology and
natural history and must be individualized to the patient,
but the general approach of the writing committee is out-
lined in Figure 4.
9.1. Asymptomatic Patients
A large proportion of patients presenting with HCM are
asymptomatic, and most will achieve a normal life expec-
tancy.213,252,253 It is essential to educate these patients and
their families about the disease process, includinggery c December 2011
FIGURE 4. Treatment algorithm. ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DM, diabetes mellitus; EF, ejection fraction;
GL, guidelines; HCM, hypertrophic cardiomyopathy; HTN, hypertension; LV, left ventricular.
Gersh et al Clinical Guidelinescreening of first-degree relatives and avoiding particularly
strenuous activity or competitive athletics.88 Risk stratifica-
tion for SCD should also be performed in all patients, irre-
spective of whether symptoms are present.32,38
Because concomitant CAD has a significant impact on
survival in patients with HCM,240 it is recommended that
other risk factors that may contribute to atherosclerotic dis-
ease be aggressively treated in concordance with existing
guidelines (Figure 4).32,86
Hydration and avoidance of environmental situations
where vasodilatation may occur are important in the asymp-
tomatic patient with resting or provocable LVOT obstruc-
tion. High-dose diuretics and vasodilators (for treatment
of other diseases such as hypertension) should be avoided,
because these may exacerbate the degree of obstruction.3,38The Journal of Thoracic and CarFinally, the indication for septal reduction therapy is to
improve symptoms that are not relieved by medical therapy
and that impair the patient’s quality of life, usually consis-
tent with NYHA functional classes III or IV.32,38 Thus,
septal reduction therapy with either septal myectomy or
alcohol septal ablation should not be performed in the
asymptomatic patient, regardless of the severity of
obstruction.32,38
9.2. Symptomatic Patients
The major goal of pharmacologic therapy in symptom-
atic patients with HCM is to alleviate symptoms of exer-
tional dyspnea, palpitations, and chest discomfort, which
may reflect pathophysiologic mechanisms such as LVOT
obstruction, reduced supply of myocardial oxygen, mitraldiovascular Surgery c Volume 142, Number 6 1319
Clinical Guideline Gersh et alregurgitation, and impaired LV diastolic relaxation and
compliance.32,38,88
Beta blockers are the mainstay of pharmacologic therapy
and the first-line agents because of their negative inotropic
effects260 and their ability to attenuate adrenergic-induced
tachycardia (Figure 4). The reduction in heart rate also pro-
longs the diastolic filling period, which may allow for more
efficient inactivation of myocardial contractile proteins,
thereby improving diastolic filling.255,256
In those patients unable to tolerate beta blockers or those
with symptoms unresponsive to beta blockers, calcium
channel blockers may provide effective symptomatic relief.
Verapamil has been the most intensively studied such agent
(Figure 4).99,257 Possible mechanisms for symptomatic
improvement include negative inotropic and rate-lowering
effects similar to those of beta blockers. However, the effect
of verapamil on diastolic dysfunction is controver-
sial.258-262 Diltiazem has also been shown to improve
measures of diastolic performance263 and to prevent or di-
minish myocardial ischemia.264 Both verapamil and diltia-
zem should be used cautiously in patients with severe
outflow tract obstruction, elevated pulmonary artery wedge
pressure, and low systemic blood pressure, because a de-
crease in blood pressure with treatment may trigger an in-
crease in outflow obstruction and precipitate pulmonary
edema. Administration of beta-blocking drugs with either
verapamil or diltiazem should also be used with caution be-
cause of the potential for high-grade atrioventricular block.
Dihydropyridine class calcium channel blockers (eg, nifed-
ipine) should not be used in patients with obstructive phys-
iology because their vasodilatory effects may aggravate
outflow obstruction.
InpatientswithobstructiveHCMwho remain symptomatic
despite the use of beta blockers and calciumchannel blockers,
alone or in combination, disopyramide may be effective in
ameliorating symptoms (Figure 4).68,265 Diuretics may be
effective for symptomatic relief in patients with pulmonary
congestion but should be used judiciously in those with
outflow tract obstruction at rest or with provocation.
9.3. Invasive Therapies
For severe refractory symptoms that are attributable to
LVOT obstruction, invasive therapies can be used to im-
prove quality of life (Figure 4). Surgical approaches have
been used for 5 decades52,220 so that relief of outflow tract
obstruction and symptoms can be achieved with minimal
perioperative morbidity or mortality in experienced
centers.64,65 However, some patients are not optimal
surgical candidates (eg, because of comorbidities or
advanced age) or have such a strong desire to avoid
surgery that alternative therapeutic interventions have
been implemented. Alcohol septal ablation, which has
been used for the past 17 years, has become the leading
strategy in these circumstances.2661320 The Journal of Thoracic and Cardiovascular Sur9.3.1. Selection of Patients
It is well recognized that the appropriate selection of pa-
tients for individual procedures is an important predictor of
outcome. Because the majority of patients with HCM can
achieve control of their symptoms with optimal pharmaco-
logic therapy, and in light of the complications inherent
with invasive therapies, a core set of clinical, anatomic,
and hemodynamic criteria are required before patients are
considered candidates for invasive therapies. Specifically,
patients must have symptoms attributable to LVOTobstruc-
tion that are refractory to optimal pharmacologic therapy.
Similarly, it must be demonstrated that the obstruction is
caused by apposition of the mitral valve with the hypertro-
phied septum.52,220 Maximal instantaneous gradients of at
least 50 mm Hg at rest or with physiologic provocation
are necessary to produce symptoms amenable to invasive
therapies.32
Given the duration of experience, documented long-term
results, and safety data, surgical septal myectomy is consid-
ered the preferred treatment for most patients who meet
these criteria (Figure 4). Considerations that favor surgical
intervention include younger age, greater septal thickness,
and concomitant cardiac disease independently requiring
surgical correction (eg, intrinsic mitral valve disease or cor-
onary artery bypass grafting). Additionally, specific abnor-
malities of the mitral valve and its support apparatus can
contribute significantly to the generation of outflow tract
obstruction, suggesting the potential value of additional sur-
gical approaches (eg, plication, valvuloplasty, and papillary
muscle relocation) and making myectomymore appropriate
than alcohol septal ablation in some patients.26,224,267-272
Among patients who meet the core selection criteria,
factors that influence a decision to proceed with alcohol
septal ablation include older or advanced age, significant
comorbidity that selectively increases surgical risk, (eg,
significant concerns about lung or airway management),
and the patient’s strong desire to avoid open heart surgery
after a thorough discussion of both options.
9.3.2. Results of Invasive Therapy for the Relief of LVOT
Obstruction
More detailed discussions specific to each type of proce-
dure follow in subsequent sections of this document. Over-
all, reports suggest that technical success, variably defined,
is achieved in 90% to 95% of patients who undergo surgical
myectomy,273 less in septal ablation, and only in the minor-
ity of patients studied in trials of pacemaker ther-
apy.132,134,135,274 Patients undergoing septal ablation may
have hemodynamic and symptomatic improvement
comparable to septal myectomy if the area of the SAM-
septal contact can be accessed by the first septal perforator
and ablated. However, compared with septal myectomy in
which the hypertrophied muscle is directly visualized and
resected, successful septal ablation is dependent on thegery c December 2011
Gersh et al Clinical Guidelinevariable septal artery anatomy, which may not supply the
targeted area of the septum in up to 20% to 25% of
patients.60,275
In a nonrandomized retrospective evaluation of patients
with HCM<65 years of age, survival free from recurrent
symptoms favored myectomy over ablation (89% versus
71%, P ¼ .01).60 Procedural success is associated with very
low mortality (<1% for myectomy,64,65,276 ranging from
0% to 4% for ablation),277-279 and low nonfatal
complication rates (2% to 3% in experienced centers). The
exception is high-grade atrioventricular block requiring per-
manent pacemakers following septal ablation (in 10% to20%
of patients), an inherent aspect of the septal infarction.279a-c
9.3.3. Operator Experience
Operator and institutional experience, including proce-
dural volume, is a key determinant of successful out-
comes and lower complication rates for any procedure.
For HCM, a disease of substantial heterogeneity and rel-
atively uncommon in general cardiology practice, this is
an important issue. As a consensus opinion, the writing
committee recommends an operator volume of at least
20 procedures or that the operator work within the con-
text of an HCM program with a cumulative procedural
volume of at least 50 procedures. In addition, given
the data available from experienced centers, operators
and institutions should aim to achieve mortality rates
of <1% and major complication rates of <3%, with
documented success in both hemodynamic and symptom
benefit for their patients. This is best achieved in the
context of a systematic program dedicated to the multi-
disciplinary and longitudinal care of patients with HCM.
9.3.4. Surgical Therapy
Transaortic septal myectomy is currently considered the
most appropriate treatment for the majority of patients with
obstructive HCM and severe symptoms unresponsive to
medical therapy (Figure 4).126,273,280-288 Surgical results,
although vastly improved in recent years, are nevertheless
limited to relatively few centers with extensive experience
and particular interest in the management of HCM.270,289
Both the traditional myectomy (Morrow procedure) with
about a 3-cm long resection284 or extended myectomy (a re-
section of about 7 cm) are currently used.270,289
The transaortic approach remains the primary method of
exposure. Virtual abolition of the LV outflow gradient and
mitral regurgitation is usually accomplished by muscular
resection resulting in physical enlargement of the outflow
tract and by interruption of the mitral valve SAM, which
is usually responsible for the outflow gradient.297
In selected circumstances, some surgeons have also used
concomitant mitral valve repair, particularly when the ante-
rior leaflet is elongated. Finally, enlarged or malpositioned
papillary muscles can also contribute to residual obstruc-
tion. This can be effectively treated by shaving theThe Journal of Thoracic and Carhypertrophied papillary muscles, incising papillary muscles
off the ventricular free wall, and in selected circumstances
repositioning one papillary muscle by suture approximation
to the adjacent papillary muscle.
9.3.4.1. Outcomes
Early Results. Based on the experience and data assembled
from multiple centers worldwide over the last 4 de-
cades,126,273,280,282,283,285,286 septal myectomy is
established as the most effective and proven approach for
reversing the consequences of heart failure by providing
amelioration of obstruction (and relief of mitral
regurgitation) at rest, with restoration of functional
capacity and acceptable quality of life at any age,
exceeding that achievable with long-term administration
of cardioactive drugs.32,290
LV outflow gradient reduction with myectomy results
from basal septal thinning with resultant enlargement of
the LVOT area (and redirection of forward flow with loss
of the drag and Venturi effects on the mitral valve)291 and
consequently abolition of SAM and mitral-septal con-
tact.289,292,293 Mitral regurgitation is also usually
eliminated without the need for additional mitral valve
surgery.56 With myectomy, left atrial size (and possibly
long-term risk for AF) is reduced65 and LV pressures (and
wall stress) are normalized.32,56,64,291,294 Thus, obstructive
HCM is a surgically and mechanically reversible form of
heart failure. In experienced centers, operative risk is now
particularly low, in the range of<1%.290
Late Results. Relief of outflow obstruction by septal
myectomy may also extend the longevity of patients with
HCM.64 Although RCTs involving myectomy surgery
have not been performed, in a nonrandomized study, myec-
tomy resulted in excellent long-term survival similar to that
in the general population. After septal myectomy, long-term
actuarial survival was 99%, 98%, and 95% at 1, 5, and 10
years, respectively (when considering HCM-related mortal-
ity). This survival rate did not differ from that expected in
a matched general US population and was superior to that
achieved by patients with obstructed HCM who did not un-
dergo surgical myectomy.64 Similarly the rate of SCD or ap-
propriate ICD discharge after myectomy is very low
(<0.9%).64,295,296 Nonetheless, surgical myectomy does
not eliminate the need to assess each patient’s risk for
SCD and to consider placement of an ICD in those with
a significant risk burden.
9.3.4.2. Complications
Complications following myectomy are rare when per-
formed in experienced centers.297 The risk of complete
heart block is approximately 2% with myectomy (higher
in myectomy patients with preexisting right bundle-
branch block), but in myectomy patients who have had pre-
vious alcohol septal ablation, risk is much higher (50% todiovascular Surgery c Volume 142, Number 6 1321
Clinical Guideline Gersh et al85%).298 Iatrogenic ventricular septal defect occurs in<1%
of patients.
9.3.4.3. Mitral Valve Abnormalities and Other Anatomic
Issues
Abnormalities of the mitral valve and subvalvar appara-
tus (including anomalous direct anterolateral papillary mus-
cle insertion into anterior mitral leaflet and elongated mitral
leaflets)224,299 can be identified preoperatively with TTE or
intraoperative TEE and can be corrected with modified
mitral valve repair or extended myectomy techniques
without the need for mitral valve replacement.
9.3.5. Alcohol Septal Ablation
First reported in 1995,266 alcohol septal ablation uses
transcoronary administration of absolute ethanol via a per-
cutaneous approach to induce a localized infarction of the
basal septum at the point of contact of the anterior mitral
valve leaflet, thereby reducing outflow tract gradient and as-
sociated mitral regurgitation and simulating the results of
surgical myectomy. Developed as an alternative to surgical
septal myectomy, the technique is particularly useful when
surgery is contraindicated and in patients who are consid-
ered poor surgical candidates.129 Since its development, al-
cohol septal ablation has been performed successfully in
a large number of patients.62
Contrast angiography of the septal perforator through the
balloon central lumenwith simultaneous echocardiographic
guidance300,301 confirms delivery to only the target
myocardium. About 1 to 3 mL of alcohol is infused in
controlled fashion.59,302-304 It is important that the balloon
be inflated and that a contrast injection also show that
there is no extravasation of dye into the distal left anterior
descending coronary artery. Contrast enhancement of
other regions (papillary muscles, free wall) indicates
collateral circulation from the septal perforator artery, and
alcohol should not be infused. A decrease in resting and
provocable gradients usually occurs immediately after the
procedure (because of stunning), and remodeling can
result in continued or variable gradient reduction over the
first 3 months after the procedure.
9.3.5.1. Selection of Patients
Alcohol septal ablation has the potential for greater pa-
tient satisfaction because of the absence of a surgical inci-
sion and general anesthesia, less overall discomfort, and
a much shorter recovery time. The benefit of alcohol septal
ablation in patients of advanced age is similar to that in
other patients.127,305 Because the postoperative risks and
complications of cardiac surgery increase with age,
ablation may offer a selective advantage in older patients,
in whom operative risk may be increased because of
comorbidities. Alcohol septal ablation is not indicated in
children.1322 The Journal of Thoracic and Cardiovascular SurOn the other hand, longer-term follow-up data are avail-
able for septal myectomy than for septal ablation, a consid-
eration relevant to the selection of patients for either septal
reduction therapy. The likelihood of implantation of a per-
manent pacemaker is 4- to 5-fold higher after septal ablation
than after septal myectomy. Furthermore, patients with
massive septal thickness approaching or exceeding 30 mm
may experience little or no benefit from septal ablation.
The surgeon can tailor the myectomy under direct visualiza-
tion to address specific anatomic abnormalities of the LVOT
or mitral valve apparatus, whereas alcohol septal ablation
indirectly (and is restricted to) targets the distribution of
the septal perforator artery.
Septal myectomy is the preferred treatment option for
most severely symptomatic patients with obstructive
HCM, especially in younger, healthy adults, whereas septal
ablation is preferred in patients for whom surgery is contra-
indicated or considered high risk (particularly the elderly)
(Figure 4). Data comparing alcohol septal ablation with sep-
tal myectomy are inadequate to fully inform clinical deci-
sion making in certain cases. For such patients, the
principle of patient autonomy dictates that it is appropriate
for the informed patient to choose between the 2
procedures.
9.3.5.2. Results
Necrosis of the basal ventricular septum306 produces an
immediate fall in gradient from decreased septal contrac-
tion in >90% of patients.66,279,307-309 This effect is
followed by LV remodeling over 6 to 12 months,
a process that includes scar retraction and resultant
widening of the outflow tract, associated with further
reduction in gradient and degree of mitral regurgitation,
regression of hypertrophy, and improvement in diastolic
function.63,279,310-312 The beneficial results of alcohol
septal ablation have been reported to almost 5 years after
the procedure with improved functional and angina
classes, exercise capacity, and quality of life.62,279,313-316
However, hemodynamic and symptomatic success is
dependent on the ability to cannulate and ablate a septal
perforator artery that supplies the area of the SAM-septal
contact.
Although RCTs comparing surgical myectomy with al-
cohol septal ablation have not been conducted and are
highly unlikely in the future, meta-analyses have noted sim-
ilar hemodynamic and functional improvement over 3 to 5
years when examining the cumulative average of out-
comes.317-319 What the meta-analyses do not report are
a subset of patients in whom alcohol septal ablation is
unreliable because of the inability to ablate the area of the
SAM-septal contact.320 Older patients, especially those
considered to be at high surgical risk, may be well served
by alcohol septal ablation, whereas younger patients may
benefit most from surgical myectomy.60,129 Despite agegery c December 2011
Gersh et al Clinical Guidelinedifferences in treatment allocation, with septal ablation
patients on average approximately 10 years older in
clinical practice,317,318 the 4-year survival rate is similar
for the 2 procedures.60,128 Most studies that have
compared surgical myectomy and alcohol septal ablation
have involved a large single-center experience in which
treatment assignment was not randomized.
9.3.5.3. Complications
In approximately half of patients undergoing alcohol sep-
tal ablation, temporary complete atrioventricular block oc-
curs during the procedure.321-323 Persistent complete heart
block prompting implantation of a permanent pacemaker
occurs in 10% to 20% of patients based on the available
data.36 Approximately 5% of patients have sustained ven-
tricular tachyarrhythmias during hospitalization. The in-
hospital mortality rate is up to 2%.60,62,129,318 Because of
the potential for creating a ventricular septal defect, septal
ablation should not be performed if the target septal
thickness is 15 mm.
Alcohol septal ablation is a therapeutic alternative to sur-
gical myectomy for selected patients and produces a trans-
mural infarction of ventricular septum occupying on
average 10% of the overall LV wall.144,275,324 There has
been concern that the potential ventricular
arrhythmogenicity of the scar created by septal ablation
might augment risk in the HCM population. Several
studies have documented the occurrence of sustained
ventricular arrhythmias301,314,325-331 and SCD following
septal ablation296 in about 3% to 10% of patients both
with or without risk factors for SCD. Patients with HCM
considered to carry sufficient risk to warrant ICD placement
have an annual incidence of appropriate interventions for
VT/ventricular fibrillation of 3% to 10%.150,328,332 It is
uncertain how common such events are attributable to the
procedure or alternatively to the underlying disease, but
the incidence of sustained ventricular arrhythmias after
myectomy is extremely low (0.2% to 0.9% per
year).64,295,296
Meta-analyses have indicated no difference between sep-
tal ablation and myectomy in the medium-term incidence of
SCD or all-cause mortality.317,333 Although no definitive
evidence is available that the ablation scar as such
increases (or does not increase) long-term risk for SCD in
absolute terms in this patient population, resolution will re-
quire greatly extended follow-up studies in larger patient
cohorts.144,325
9.3.6. DDD Pacing
Implantation of a dual-chamber pacemaker was proposed
as an alternative treatment for patients with severe symptom-
atic obstructive HCM.335-337 However, there have been 3
randomized crossover trials showing that although
symptomatic improvement was reported by the majority of
patients following continuous DDD pacing, a similarThe Journal of Thoracic and Carfrequency of improvement was reported by patients during
the AAI mode (control mode without pacing). These
findings suggest a placebo effect responsible for the
perceived improvement in symptoms.136,137,338 However,
there is some evidence that patients>65 years of age may
be a subgroup who achieve the greatest benefit.136 There
are no data that dual-chamber pacing either reduces the risk
of SCD in patients with HCM, alters the underlying progres-
sion of disease, or is of benefit to patientswith nonobstructive
HCM.136,335,339 A trial of dual-chamber pacing may be con-
sidered for symptomatic patients with obstruction in whom
an ICD has already been implanted for high-risk status.
9.3.7. LV Systolic Dysfunction
Standard heart failure therapies should be implemented
in patients with HCM when EF is 50%. Patients with
HCM were not included in the primary prevention ICD tri-
als for patients with heart failure due to CAD or dilated car-
diomyopathy (and reduced EF). Prophylactic ICD
implantation is nevertheless the generally accepted clinical
practice for HCM patients with systolic dysfunction.9.4. Prevention of SCD
A minority of clinically recognized patients with HCM
are judged to be at increased risk for SCD, with a rate of
about 1% per year.143-146,148,150 ICDs offer the only
effective means of preventing SCD and prolonging life in
patients with HCM.150 Selection of patients who are appro-
priate for implantation for primary as opposed to secondary
prevention can be a difficult clinical decision owing to the
individuality of each patient and family, variable definitions
for risk markers, sparse clinical data, the relative infre-
quency of both HCM and SCD in most clinical practices,
and the cumulative morbidity of living with an ICD.
9.4.1. Established Risk Markers
9.4.1.1. Prior Personal History of Ventricular Fibrillation,
SCD, or Sustained VT
As expected, patients with HCM who have experienced
SCD or sustained VT represent the highest risk for subse-
quent arrhythmogenic events. The annualized rate of subse-
quent events is approximately 10% per year, although it has
been shown that individuals may have no recurrent events or
may have decades-long arrhythmia-free intervals between
episodes.145,146,148,150,340
9.4.1.2. Family History of SCD
It has been recognized that SCD events can cluster in
families. Notably, some studies have not demonstrated an
independent link between family history of SCD and risk
for individual patients on multivariate analysis,147,149,155
whereas others have suggested that family history is an
independent predictor.155 These differences may bediovascular Surgery c Volume 142, Number 6 1323
Clinical Guideline Gersh et alexplained in part by the relative infrequency of events but
also likely reflect variability in the definition of a family his-
tory of SCD.
9.4.1.3. Syncope
Syncope represents a complex symptom with a multifac-
torial etiology that requires a careful clinical history before
it can be considered a potential marker for SCD.147,152 In
one analysis, syncope that was unexplained or thought to
be consistent with arrhythmia (ie, not neurally mediated)
showed a significant independent association with SCD
only when the events occurred in the recent past (<6
months).152
9.4.1.4. Nonsustained Ventricular Tachycardia
Although sustained ventricular arrhythmia is clearly
associated with SCD, the data for NSVT are less robust.
However, 1 contemporary study showed that NSVT is inde-
pendently associated with SCD on multivariate analysis30
and is more important in younger patients (<30 years of
age).33 Furthermore, exercise-induced NSVT has been
found to have independent association with SCD.341
NSVT probably should not be considered in a simply binary
manner (ie, as either positive or negative), and there may be
some value in long-term ambulatory monitoring when
NSVT is discovered on the screening 24-hour assessment.
9.4.1.5. Maximum LV Wall Thickness
The relationship between severity of LV hypertrophy and
SCD has been investigated in several studies predicated on
the concept that the more severe the disease expression, the
more likely the individual patient is to experience adverse
events. Most, but not all,156,342 studies have shown at
least a univariate association between maximum wall
thickness and SCD,148,342,343 whereas other large studies
have shown that when magnitude of hypertrophy is 30
mm, there is an independent association with
SCD.147,152,158
9.4.1.6. Abnormal Blood Pressure Response During Exer-
cise
For up to a third of patients with HCM, there is an inap-
propriate systemic systolic blood pressure response during
exercise testing (defined as either a failure to increase by
at least 20 mm Hg or a drop of at least 20 mm Hg during ef-
fort).70,71 Two studies have shown a univariate association
between this finding and subsequent SCD.30,71,147,149
9.4.2. Other Potential SCD Risk Modifiers
9.4.2.1. LVOT Obstruction
Although some studies have not found a significant asso-
ciation between LVOT obstruction and SCD,51,158,212 other
studies have found higher rates of SCD among patients1324 The Journal of Thoracic and Cardiovascular Surwith resting gradients 30 mm Hg30,149 and that the risk
is positively correlated with severity of LVOT
obstruction.30 Conversely, relief of outflow tract obstruc-
tion through surgical myectomy is associated with very
low rates of SCD.64,307 A limitation to using LVOT
obstruction as an independent risk marker is that the
obstruction in HCM is dynamic and highly variable.225,344
9.4.2.2. LGE on CMR Imaging
There has been considerable interest in promoting LGE
on CMR imaging as a potential SCD risk marker in
HCM. Because LGE is believed to represent myocardial fi-
brosis or scarring, it has been hypothesized that LGE may
represent myocardium prone to ventricular tachyarrhyth-
mia.82 Indeed, LGE has been associated with NSVT and
ventricular ectopy but has not been associated with clinical
SCD events or ICD discharge in published studies.78,79,82
More recent studies have shown a relationship between
LGE and SCD and heart failure, but with low positive
predictive accuracy.80,81
9.4.2.3. LV Apical Aneurysm
A subset of patients with HCM (prevalence about 2%)
develop a thin-walled LV apical aneurysm associated with
regional scarring75 and more adverse clinical events dur-
ing follow-up, including progressive heart failure and
evolution into the end-stage phase, as well as SCD. Al-
though data on LV aneurysms in HCM are limited, this
abnormality may warrant consideration in SCD risk-
assessment strategies.
9.4.2.4. Genetic Mutations
SCD may cluster in certain families with HCM, and the
possibility that specific sarcomere mutations may confer
SCD risk has been hypothesized. Indeed, several early
studies of HCM pedigrees implicated certain mutations
as ‘‘malignant.’’20,227,345,346 However, subsequent studies
of less selected consecutive patients with HCM found
that it was problematic to infer likelihood of SCD
events on the basis of the proposed mutations, because
in some instances the rate of adverse events (and
prevalence of associated SCD risk markers) was lower
in patients with ‘‘malignant’’ mutations than it was in
those with mutations believed to be ‘‘benign.’’8,347-349
The data from unselected consecutive outpatients suggest
that most mutations are ‘‘novel’’ and limited to
particular families (‘‘private’’ mutations). Therefore,
routine mutational screening would appear to be of little
prognostic value in HCM.
9.4.3. Utility of SCD Risk Markers in Clinical Practice
Other than cardiac arrest, each of the HCM risk factors
has low positive predictive value (approximately 10% to
20%) and modestly high negative predictive value (85%gery c December 2011
Gersh et al Clinical Guidelineto 95%). Multiple risk markers in individual patients would
intuitively suggest greater risk for SCD; however, the vast
majority of patients with1 risk marker will not experience
SCD, and simple arithmetic summing of risk markers is not
precise because of the uncertainty implicit in assigning a rel-
ative weight to any individual risk factor.147,156,350 Notably,
in the international HCM-ICD registry,150 the number of
risk factors did not correlate with the rate of subsequent ap-
propriate ICD discharges among presumably high-risk pa-
tients selected for ICD placement. These data suggest that
the presence of a single risk marker may be sufficient to
warrant ICD placement in many patients, but these deci-
sions need to be individualized with respect to age, the
strength of the risk factor, and the risk-benefit of lifelong
ICD therapy.150,3519.5. ICD Therapy in HCM
Although the overall rate of SCD in HCM is approxi-
mately 1% per year, clearly there are individuals at higher
risk for whom prophylactic therapy may be indicated. Phar-
macologic therapy has not been demonstrated to provide
protection from SCD. Conversely, the ICD has proved to
be effective in terminating life-threatening ventricular
tachyarrhythmia in HCM, altering the natural course of
the disease and prolonging life.
The decision for placement of primary prevention ICD in
HCM often involves a large measure of individual clinical
judgment, particularly when the evidence for risk is ambig-
uous. The potential for SCD needs to be discussed with each
fully informed HCM patient and family member in the con-
text of their concerns and anxieties and should be balanced
against the risks and benefits of proposed prophylactic ICD
strategy. Consideration of the patient’s age is warranted,
particularly because device complications are more likely
in children and young adults over the long period of
follow-up.150,351
There have been 2 reports from an international, mul-
ticenter registry of patients with HCM who have under-
gone ICD placement on the basis of the clinical
perception of SCD sufficient to justify device ther-
apy.150,153 Among patients who received a device as
a result of a prior personal history of cardiac arrest or
sustained ventricular arrhythmia (secondary prevention
ICD), the annualized rate of subsequent appropriate
ICD discharge was 10% per year. Patients with primary
prevention ICDs placed on the basis of 1 or more of the
conventional risk markers experienced appropriate ICD
therapy at a rate of 4% per year.150,153 The number of
risk markers present did not predict subsequent device
discharge.150,351
9.5.1. Complications of ICD Therapy in HCM
It is important to recognize and discuss with patients
potential ICD-related complications (both proceduralThe Journal of Thoracic and Carand long term) that occur at a rate of 4% per year in pa-
tients with HCM.351 Potential early problems may include
pneumothorax, pericardial effusion, pocket hematoma,
acute pocket infection, and/or lead dislodgment. Late
complications include upper extremity deep venous
thrombosis, lead dislodgment, infection, high defibrilla-
tion threshold necessitating lead revision, and inappropri-
ate shocks, that is, shocks triggered by supraventricular
arrhythmias, sinus tachycardia, lead fractures or dislodg-
ment, oversensing, double counting, and programming
malfunctions.
Reported rates of complications include approximately
25% of patients with HCM who experienced inappropriate
ICD discharge; 6% to 13% who experienced lead compli-
cations (fracture, dislodgment, oversensing); 4% to 5%
who developed a device-related infection; and approxi-
mately 2% to 3% who experienced bleeding or thrombosis
complications.150,351 The rate of inappropriate shocks and
lead fractures appears to be higher in children than in
adults, largely because their activity level and body
growth places continual strain on the leads, which are
the weakest link in the system.143 ICD leads fail at a rate
of 0.5% to 1% per year, although there are data showing
that failure rates are increased in younger populations.160
This issue is of particular concern, given the long periods
that young patients will have prophylactically implanted
devices.
Industry-related ICD problems have affected patients
with HCM. Prominent recalls have included defective gen-
erators leading to several deaths352 and small-diameter
high-voltage leads prone to fracture.160,353 The implant
procedure has been largely free of significant risk, without
reported deaths, although selected patients with extreme
hypertrophy or who have received amiodarone may
require high-energy output generators or epicardial lead
systems.354
In patients with LVOT obstruction in whom ICDs are in-
dicated, dual-chamber pacing may have the potential to re-
duce gradient and symptoms (Section 2.10). In general, the
younger the patient, the more appropriate it is for single-
chamber devices to be used to decrease the amount of hard-
ware in the venous system.
9.6. Participation in Competitive or Recreational
Sports and Physical Activity
A number of large cohort studies from the United States
indicate that HCM is the most common cardiovascular
cause of SCD in young athletes, accounting for about one
third of these events.166-168,355 The American College of
Cardiology Bethesda Conference No. 36,163,339 as well as
the European Society of Cardiology guidelines164,356
indicate that risk for SCD is increased during intense
competitive sports and also suggest that the removal of
these individuals from the athletic arena can diminishdiovascular Surgery c Volume 142, Number 6 1325
FIGURE 5. Management of AF in HCM. AF, Atrial fibrillation; AV, atrio-
ventricular; INR, international normalized ratio; PPM, permanent pace-
maker; PVI, pulmonary vein isolation.
Clinical Guideline Gersh et altheir risk. This principle is the basis for disqualification of
athletes with HCM from sanctioned high school and
college sports.163,356 It should be underscored that these
consensus recommendations for competitive athletes are
independent of those for noncompetitive, informal
recreational sporting activities.87
General recommendations for recreational exercise in pa-
tients with HCM should be tailored to the individual’s de-
sires and abilities; however, certain guidelines prevail. For
example, aerobic exercise as opposed to isometric exercise
is preferable. Patients with HCM should avoid recreational
sports in which participation is intense and simulates com-
petitive organized athletics. Also, burst exertion, in which
an abrupt increase in heart rate is triggered (eg, sprinting
in half-court basketball), is less desirable than swimming
laps or cycling. Finally, it is prudent for such patients to
avoid physical activity in extreme environmental conditions
of heat, cold, or high humidity, with attention paid to main-
taining volume status. Detailed recommendations for indi-
vidual sports appear in Table 2.
9.7. Atrial Fibrillation
AF is an important cause of symptoms, morbidity, and
even mortality in patients with HCM.50,172 Patients with
HCM are at increased risk of AF compared with age-
matched cohorts, but AF is seldom seen in patients with
HCM who are<30 years of age and becomes more preva-
lent with age. AF occurring in HCM may not be associated
with symptoms or hemodynamic compromise in one third
of patients but is poorly tolerated in many others. There is
evidence that AF is an indicator of unfavorable prognosis,
including increased risk of HCM-related heart failure,
death, and stroke.172,357
Therapy for AF includes prevention of thromboembolic
stroke and controlling symptoms (Figure 5). The risk of sys-
temic embolization is high in patients with HCM with AF
but is not related to the severity of symptoms.50,172
Occurrence of paroxysmal, persistent, or chronic AF is
a strong indication for anticoagulation with a vitamin K
antagonist.170 Whether there is a threshold for AF that war-
rants anticoagulation is unresolved; however, given the high
risk of thromboembolism in HCM, even patients with short
episodes of AF should be strongly considered for anticoagu-
lation. Aspirin should be reserved for those who cannot or
will not take warfarin or other oral anticoagulants, but its ef-
ficacy in HCM is unestablished.
Symptom control may be attained with adequate rate
control, although many patients will require rhythm control.
Rate control is best maintained by beta blockers and cal-
cium channel blockers. High doses of these agents may be
required. Digoxin may modestly reduce ventricular rate at
rest and to a lesser extent with exertion. Because there is
a paucity of data on rhythm control in patients with
HCM, evidence from other patient populations is1326 The Journal of Thoracic and Cardiovascular Surextrapolated to HCM. However, whether patients with
HCM respond similarly to antiarrhythmic agents is not
clear. The ‘‘2011 ACCF/AHA/HRS Focused Updates In-
corporated Into the ACC/AHA/ESC 2006 Guidelines for
the Management of Patients With Atrial Fibrillation’’ state
that disopyramide and amiodarone are potential agents for
rhythm control.170 The limited published data on amiodar-
one suggest that it is safe and effective for patients with
HCM.358-361 Disopyramide has been shown to be safe
when prescribed for reduction of LVOT obstruction, but
its safety and efficacy in AF are not well established.68,362
Dronedarone, an antiarrhythmic agent similar to
amiodarone but lacking the iodine moiety and much of
the long-term toxicity, has been approved for use in the
United States. There are no data regarding the efficacy of
dronedarone or the use of flecainide and propafenone in pa-
tients with HCM. The management of atrial flutter in HCM
is similar to that in other disease states, including the role of
radiofrequency ablation.
The long-term benefits of radiofrequency ablation
versus antiarrhythmic drugs in patients with HCM re-
main to be established. It does appear that early success
and complication rates are similar between HCM and
other forms of heart disease or absence of heart dis-
ease.175,178,179,363 The surgical maze procedure for AF
has shown some limited success364; however, whether
a prophylactic or therapeutic surgical maze procedure
is indicated for patients undergoing other open chest
surgical procedures (ie, septal myectomy) is
unresolved.gery c December 2011
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In 2002, the US Department of Transportation Federal
Motor Carrier Safety Administration published its ‘‘Cardio-
vascular Advisory Panel Guidelines for the Medical Exami-
nation of Commercial Motor Vehicle Drivers.’’ The
guidelines state that ‘‘irrespective of symptoms, a person
shouldnot be certified as a [commercialmotor vehicle] driver
if a firm diagnosis of [HCM] is made..’’365(p83)k Although
consideration has subsequently been given to liberalizing
this restriction, the guidelines have not yet been revised.
The criteria for the disqualification of aircraft pilots with
cardiovascular disease are set by the Federal Aviation Ad-
ministration. Currently, HCM is regarded as generally in-
compatible with the highest grade aviation license for
commercial pilots, based on the unpredictable risk for im-
pairment in the cockpit attributable to HCM.367STAFF
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